5.8. Analysis.

Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 8: Quality of Life ‐ Quality adjusted Progression‐free survival (QA‐PFS)

Comparison 5: Platinum‐sensitive recurrent EOC: PARPi monotherapy compared with placebo after chemotherapy (maintenance therapy), Outcome 8: Quality of Life ‐ Quality adjusted Progression‐free survival (QA‐PFS)